ClinicalTrials.gov
public full text
Public Domain
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
head-and-neck-cancerhead-and-neck-squamous-cell-carcinomanon-small-cell-lungnon-small-cell-lung-cancer
A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs#1114723
- Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC#1127826
- Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC#160372
- Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma#885547
- A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations#904116
Record · ID 992751
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive